STXS at a glance
Stereotaxis, Inc. (STXS, SEC CIK 1289340) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Stereotaxis, Inc. (STXS) reported revenue of $32.4 million (up 20.3% from FY2024) and a net loss of $21.6 million. Diluted EPS was -$0.25.
- As of September 30, 2026, 18 institutional investment managers tracked by SignalX reported holding Stereotaxis, Inc. (STXS) shares worth $13.2 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Menawat Arun Swarup on November 17, 2026 of 121,561 shares at $0.82 per share.
- In the last 90 days, STXS insiders reported 4 open-market purchases ($136K) and 0 open-market sales ($0) on Form 4, a net purchase of $136K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $32.4M
- +20.3% vs prior year
- Insiders · 90 days
- 4 buys · 0 sells
- Net +$136K
- 13F holders
- 18 funds
- $13.2M · −2 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 2.02 · Item 2.03 · Item 3.02 · Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Robocath acquisition: supplemental risk factors added in Exhibit 99.1 to July 15, 2026 Form 8-K
- No material changes to previously disclosed 2025 Form 10-K risks outside the acquisition-related supplement
Management Discussion & Analysis
- Q3 revenue $8.9M, up 20% YoY from $7.5M, driven by systems revenue rising to $3.0M from $1.9M
- Overall gross margin 44% vs 55% YoY, with disposables, service and accessories margin 59% vs 67%
- Best performer: systems revenue up to $3.0M from $1.9M; weakest margin: disposables, service and accessories, down to 59% from 67%
- Cash $4.0M at September 30; operating cash use $11.3M, investing cash use $4.2M, financing cash inflow $6.0M
- Outlook: additional 2026 losses expected; tariff uncertainty, hospital spending delays and supply-chain disruptions remain headwinds
AI summary of the STXS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced by Stereotaxis on November 10, 2026
- Full results and management commentary available in Exhibit 99.1, the earnings press release
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 confirms new indebtedness through the Notes referenced under Item 1.01
- Debt terms, principal amount, interest rate, maturity and use of proceeds require review of Item 1.01
Item 3.02: Unregistered Sales of Equity Securities
- Private issuance of Notes and related shares under the Note Financing, outside a public offering
- Financing completion and additional draws remain subject to required regulatory approvals
Item EX-99.2: Item EX-99.2
- Up to $24 million convertible financing: $12 million upfront plus $12 million available after regulatory milestones
- 10% annual interest, accrued until maturity in three years, increasing future cash obligations
Item 1.01: Entry into a Material Definitive Agreement
- $12.0M initial convertible note financing closed, with potential additional proceeds up to $12.0M
- Notes carry 10% annual interest, mature November 9, 2029, and generally defer interest through payment-in-kind accrual
Item EX-99.1: Item EX-99.1
- Q3 revenue $8.9M, up 20% year over year and 16% sequentially, led by system revenue growth to $3.0M
- Recurring revenue $5.9M, up 6% year over year but down 4% sequentially amid catheter supply constraints
Item EX-99.1: Item EX-99.1
- Q2 revenue $7.7M, down from $8.8M, as system revenue fell to $1.5M from $3.0M
- Recurring revenue rose to $6.2M, with robotic catheter revenue exceeding $1M and growing 270% sequentially
Item 2.02: Results of Operations and Financial Condition
- Stereotaxis announced fiscal 2026 second-quarter financial results on August 11, 2026
- Detailed results and management commentary are contained in Exhibit 99.1, the Earnings Press Release
Item 8.01: Other Events
- Acquisition closed July 7, 2026, giving Stereotaxis 100% of Robocath’s shares and voting power
- Robocath transaction expands Stereotaxis’ ownership and operating exposure to the French medical-technology business
Item EX-99.1: Item EX-99.1
- Robocath acquisition expected to increase near-term operating losses and negative cash flow, requiring potential funding of its operations
- $1.1 million in pre-closing operating loans repaid at closing, reducing stock consideration paid to Robocath equityholders
AI summaries of STXS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for STXS
Don't miss the next STXS filing
- Alerts as it files. A push when STXS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut STXS, by share count.
- Ask anything. An AI agent that reads every STXS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Menawat Arun Swarup | Buy | Nov 17, 2026 | 121,561 | $0.82 |
| Isaac Paul J | Buy | Nov 17, 2026 | 300 | $0.80 |
| Benfer David | Buy | Nov 17, 2026 | 30,000 | $0.83 |
| Isaac Paul J | Buy | Nov 16, 2026 | 13,000 | $0.82 |
| Fischel Nathan | Buy | Nov 9, 2026 | - | - |
| DAFNA Capital Management LLC | Buy | Nov 9, 2026 | - | - |
| Benfer David | A | Jul 1, 2026 | 43,103 | - |
| Curet Myriam | A | Jul 1, 2026 | 43,103 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $26.9M | $32.4M |
| Gross Profit | $14.9M | $14.6M | $17.1M |
| Operating Income | - | -$24.7M | -$22.1M |
| Net Income | -$20.7M | -$24.0M | -$21.6M |
| Gross Margin | - | 54.2% | 52.7% |
| Op. Margin | - | -91.9% | -68.3% |
| Net Margin | - | -89.3% | -66.8% |
| Balance Sheet | |||
| Total Assets | $41.9M | $46.7M | $52.3M |
| Equity | - | $6.1M | $13.5M |
| ROE | - | -395.5% | -160.5% |
| Per Share | |||
| EPS | $-0.27 | $-0.30 | $-0.25 |
| Cash Flow | |||
| Operating CF | - | -$8.5M | -$13.7M |
Source: XBRL data in Stereotaxis, Inc. (STXS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate STXS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 18 | $13.2M |
| Q2 2026 | 20 | $18.9M |
| Q1 2026 | 20 | $18.8M |
| Q4 2025 | 21 | $24.5M |
| Q3 2025 | 20 | $32.6M |
| Q2 2025 | 19 | $19.9M |
| Q1 2025 | 18 | $10.5M |
| Q4 2024 | 12 | $12.8M |
- BNY Mellon+98.4K (+47%)
- Goldman Sachs Group+94.4K (+40%)
- T. Rowe Price Group+32.2K (+23%)
- Northern Trust+32.2K (+6%)
- Bank of America Corp+27.8K (+24%)
- Morgan Stanley−159.4K (-48%)
- AQR Capital Management−126.0K (-64%)
- Wells Fargo & Co−39.5K (-63%)
- Vanguard Capital Management LLC−34.9K (-1%)
- Citigroup−28.6K (-89%)
- Citadel Advisors LLC−183.1K
- FMR LLC (Fidelity)−24.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 148 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
STXS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 10-Q | Nov 16, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| SC 13G | Aug 19, 2026 | - | - | |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 8-K | Jul 9, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | May 15, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 8-K | Apr 15, 2026 | - | Analysis | - |
| 4 | Apr 13, 2026 | - | - | - |
| 10-K | Mar 12, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 9, 2026 | - | Analysis | - |
Related Health Care companies
- AXGN · Axogen, Inc.Electromedical & Electrotherapeutic Apparatus
- BLFS · BIOLIFE SOLUTIONS INCElectromedical & Electrotherapeutic Apparatus
- CV · CapsoVision, IncElectromedical & Electrotherapeutic Apparatus
- CBLL · Ceribell, Inc.Electromedical & Electrotherapeutic Apparatus
- CNMD · CONMED CorpElectromedical & Electrotherapeutic Apparatus
- ELMD · Electromed, Inc.Electromedical & Electrotherapeutic Apparatus
- HYPR · Hyperfine IncElectromedical & Electrotherapeutic Apparatus
- ITGR · Integer Holdings CorpElectromedical & Electrotherapeutic Apparatus
STXS SEC filings: frequently asked questions
Are STXS insiders buying or selling?
In the last 90 days, Stereotaxis, Inc. (STXS) officers, directors and 10% owners reported 4 open-market purchases worth $135,754 by 3 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold STXS stock?
As of September 30, 2026, the largest Stereotaxis, Inc. (STXS) holders among the 13F filers tracked by SignalX were BlackRock ($5.4 million), Vanguard Capital Management LLC ($3.7 million), State Street Corp ($1.1 million), Northern Trust ($692,000), Vanguard Portfolio Management LLC ($588,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was STXS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Stereotaxis, Inc. (STXS) reported revenue of $32.4 million (up 20.3% from FY2024) and a net loss of $21.6 million. Diluted EPS was -$0.25. The figures come from the XBRL data in the 10-K.
What did STXS report in its latest 8-K?
Stereotaxis, Inc. (STXS) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities) and Item 1.01 (Entry into a Material Definitive Agreement). Q3 2026 financial results announced by Stereotaxis on November 10, 2026.
What are the latest STXS SEC filings?
Stereotaxis, Inc. (STXS) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 18, 2026.
What is STXS's SEC CIK number?
Stereotaxis, Inc. (STXS)'s SEC Central Index Key (CIK) is 1289340. EDGAR lists every STXS filing under that number.
Ask anything about STXS
The research agent reads STXS's filings, financials, insider trades and 13F holders, then answers with sources.